Skip to content

Dactinomycin

FDA-approved product (injectable, injection), marketed as Cosmegen, Dactinomycin.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Dactinomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Kidney Wilms tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Actinomycines
FDA pharmacologic class
Actinomycin FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA95.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dactinomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

    NCT00379457 · start 2006-06

    Registered record
    Registry ID
    NCT00379457
    Conditions
    Sarcoma
    Interventions
    dactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; ifosfamide; topotecan hydrochloride; vincristine sulfate; vinorelbine tartrate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2006-06
    Completion
    Not recorded
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride +7 more
    PhasePhase 3
    Registry statusUnknown
  • Pharmacokinetics of Dactinomycin in Young Patients With Cancer

    NCT00900354 · start 2006-06

    Registered record
    Registry ID
    NCT00900354
    Conditions
    Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions
    molecular genetic technique; mass spectrometry; pharmacological study
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2006-06
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Childhood Solid Tumor, Protocol Specific
    Interventionmolecular genetic technique; mass spectrometry; pharmacological study
    PhaseNot recorded
    Registry statusUnknown
  • Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

    NCT00075582 · start 2004-09-04

    Registered record
    Registry ID
    NCT00075582
    Conditions
    Adult Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Embryonal-botryoid Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma
    Interventions
    conventional surgery; dactinomycin; cyclophosphamide; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-09-04
    Completion
    2021-09-30
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Embryonal-botryoid Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma
    Interventionconventional surgery; dactinomycin; cyclophosphamide; vincristine sulfate +1 more
    PhasePhase 3
    Registry statusCompleted
  • A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer

    NCT00491946 · start 2004-06

    Registered record
    Registry ID
    NCT00491946
    Conditions
    Cancer
    Interventions
    Actinomycin-D; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2004-06
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionActinomycin-D; Vincristine
    PhasePhase 4
    Registry statusUnknown
  • Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma

    NCT00245141 · start 2004-05

    Registered record
    Registry ID
    NCT00245141
    Conditions
    Sarcoma
    Interventions
    dactinomycin; cyclophosphamide; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2004-05
    Completion
    Not recorded
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; cyclophosphamide; vincristine sulfate; radiation therapy
    PhasePhase 2
    Registry statusUnknown
  • Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma

    NCT00541411 · start 2003-06

    Registered record
    Registry ID
    NCT00541411
    Conditions
    Ewing's Sarcoma
    Interventions
    Vincristine, Actinomycin-D, Ifosfamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2003-06
    Completion
    2013-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing's Sarcoma
    InterventionVincristine, Actinomycin-D, Ifosfamide
    PhaseNot applicable
    Registry statusUnknown
  • Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

    NCT00003958 · start 2002-09

    Registered record
    Registry ID
    NCT00003958
    Conditions
    Adult Malignant Mesenchymoma; Adult Rhabdomyosarcoma; Alveolar Childhood Rhabdomyosarcoma; Childhood Malignant Mesenchymoma; Embryonal Childhood Rhabdomyosarcoma; Embryonal-botryoid Childhood Rhabdomyosarcoma; Nonmetastatic Childhood Soft Tissue Sarcoma; Previously Untreated Childhood Rhabdomyosarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma
    Interventions
    dactinomycin; vincristine sulfate; cyclophosphamide; therapeutic conventional surgery; radiation therapy; topotecan hydrochloride; filgrastim; sargramostim; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-09
    Completion
    Not recorded
    Enrolment
    702

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Malignant Mesenchymoma; Adult Rhabdomyosarcoma; Alveolar Childhood Rhabdomyosarcoma; Childhood Malignant Mesenchymoma +7 more
    Interventiondactinomycin; vincristine sulfate; cyclophosphamide; therapeutic conventional surgery +5 more
    PhasePhase 3
    Registry statusCompleted
  • Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

    NCT00020566 · start 2001-02

    Registered record
    Registry ID
    NCT00020566
    Conditions
    Sarcoma
    Interventions
    dactinomycin; busulfan; doxorubicin hydrochloride; etoposide; ifosfamide; melphalan; vincristine sulfate; autologous hematopoietic stem cell transplantation; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2001-02
    Completion
    Not recorded
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; busulfan; doxorubicin hydrochloride; etoposide +6 more
    PhasePhase 3
    Registry statusUnknown
  • Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor

    NCT00047138 · start 2001-01

    Registered record
    Registry ID
    NCT00047138
    Conditions
    Kidney Cancer
    Interventions
    dactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; vincristine sulfate; adjuvant therapy; conventional surgery; neoadjuvant therapy; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2001-01
    Completion
    Not recorded
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    Interventiondactinomycin; carboplatin; cyclophosphamide; doxorubicin hydrochloride +6 more
    PhasePhase 3
    Registry statusUnknown
  • Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

    NCT00003955 · start 1999-09

    Registered record
    Registry ID
    NCT00003955
    Conditions
    Sarcoma
    Interventions
    dactinomycin; filgrastim; pegfilgrastim; sargramostim; cyclophosphamide; irinotecan hydrochloride; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-09
    Completion
    2009-10
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; filgrastim; pegfilgrastim; sargramostim +4 more
    PhasePhase 2
    Registry statusCompleted
  • Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia

    NCT00003702 · start 1999-06

    Registered record
    Registry ID
    NCT00003702
    Conditions
    Good Prognosis Metastatic Gestational Trophoblastic Tumor; Hydatidiform Mole; Non-Metastatic Gestational Trophoblastic Tumor; Uterine Corpus Choriocarcinoma
    Interventions
    Dactinomycin; Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-06
    Completion
    Not recorded
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGood Prognosis Metastatic Gestational Trophoblastic Tumor; Hydatidiform Mole; Non-Metastatic Gestational Trophoblastic Tumor; Uterine Corpus Choriocarcinoma
    InterventionDactinomycin; Methotrexate
    PhasePhase 3
    Registry statusCompleted
  • Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

    NCT00025441 · start 1998-11

    Registered record
    Registry ID
    NCT00025441
    Conditions
    Ovarian Cancer; Sarcoma; Small Intestine Cancer
    Interventions
    dactinomycin; filgrastim; carboplatin; cyclophosphamide; doxorubicin hydrochloride; epirubicin hydrochloride; etoposide; ifosfamide; vincristine sulfate; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-11
    Completion
    2010-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Sarcoma; Small Intestine Cancer
    Interventiondactinomycin; filgrastim; carboplatin; cyclophosphamide +7 more
    PhasePhase 2
    Registry statusCompleted
  • Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

    NCT00002995 · start 1997-08

    Registered record
    Registry ID
    NCT00002995
    Conditions
    Sarcoma
    Interventions
    dactinomycin; filgrastim; sargramostim; cyclophosphamide; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-08
    Completion
    2011-01
    Enrolment
    483

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventiondactinomycin; filgrastim; sargramostim; cyclophosphamide +2 more
    PhasePhase 3
    Registry statusCompleted
  • Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

    NCT00002766 · start 1996-03

    Registered record
    Registry ID
    NCT00002766
    Conditions
    Leukemia; Lymphoma
    Interventions
    dactinomycin; sargramostim; carmustine; cyclophosphamide; cytarabine; daunorubicin hydrochloride; doxorubicin hydrochloride; etoposide; mercaptopurine; methotrexate; mitoxantrone hydrochloride; pegaspargase; prednisone; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-03
    Completion
    2011-09
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventiondactinomycin; sargramostim; carmustine; cyclophosphamide +11 more
    PhasePhase 3
    Registry statusCompleted
  • Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

    NCT00002610 · start 1996-01

    Registered record
    Registry ID
    NCT00002610
    Conditions
    Kidney Cancer
    Interventions
    dactinomycin; filgrastim; carboplatin; cyclophosphamide; doxorubicin hydrochloride; etoposide; vincristine sulfate; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-01
    Completion
    2006-02
    Enrolment
    203

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    Interventiondactinomycin; filgrastim; carboplatin; cyclophosphamide +5 more
    PhasePhase 3
    Registry statusCompleted